Jpmorgan Chase & CO Greenwich Life Sciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,548 shares of GLSI stock, worth $34,245. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,548
Previous 5,672
55.08%
Holding current value
$34,245
Previous $113,000
61.95%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding GLSI
# of Institutions
35Shares Held
1.01MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY309KShares$4.15 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA268KShares$3.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA128KShares$1.72 Million0.0% of portfolio
-
Credit Agricole S A87KShares$1.17 Million0.01% of portfolio
-
State Street Corp Boston, MA68.4KShares$919,3360.0% of portfolio
About Greenwich LifeSciences, Inc.
- Ticker GLSI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,848,200
- Market Cap $173M
- Description
- Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...